Guggenheim Capital LLC Xenon Pharmaceuticals Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 10,629 shares of XENE stock, worth $413,468. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,629

Previous 11,290 5.85%

Holding current value

$413,468

Previous $440,000 5.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$36.12 - $43.96 $23,875 - $29,057	-661 Reduced 5.85%	10,629 $418,000
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $3,552 - $4,287	-98 Reduced 0.86%	11,290 $440,000
Q1 2024 May 14, 2024	BUY	$42.66 - $50.04 $79,304 - $93,024	1,859 Added 19.51%	11,388 $490,000
Q4 2023 Feb 14, 2024	SELL	$28.7 - $46.46 $46,006 - $74,475	-1,603 Reduced 14.4%	9,529 $438,000
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $25,893 - $30,115	758 Added 7.31%	11,132 $380,000
Q2 2023 Aug 11, 2023	SELL	$34.84 - $43.54 $308,264 - $385,241	-8,848 Reduced 46.03%	10,374 $399,000
Q1 2023 May 10, 2023	BUY	$33.46 - $40.35 $4,316 - $5,205	129 Added 0.68%	19,222 $687,000
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $137,364 - $163,831	4,155 Added 27.81%	19,093 $752,000
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $17,273 - $22,339	561 Added 3.9%	14,938 $539,000
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $4,680 - $6,469	184 Added 1.3%	14,377 $437,000
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $12,770 - $16,863	509 Added 3.72%	14,193 $434,000
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $56,300 - $127,758	3,609 Added 35.82%	13,684 $427,000
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $149,714 - $195,958	10,075 New	10,075 $154,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Xenon Pharmaceuticals Inc. Transaction History